COMMUNIQUÉS West-GlobeNewswire

SCIENTURE Provides Commercial Update on ARBLI™, the First FDA-Approved Ready-to-Use Oral Suspension of Losartan Potassium
03/02/2026
Company highlights accelerating access and revenue growth for ARBLI ™ and confirms REZENOPY ™ launch timeline, addressing a combined US annual losartan and naloxone market size of close to $385 million Outlines Q1 2026 [...]
Enovis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
03/02/2026
Dallas TX, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that management will participate in the BTIG 13th Annual MedTech, [...]
Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026
03/02/2026
PRINCETON, N.J., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced the presentation of new data from clinical and real-world studies of Galafold ® (migalastat) in Fabry disease and [...]
HOOKIPA Pharma Announces Sale of Oncology Assets to NeoTrail Therapeutics
03/02/2026
Next-generation therapeutic cancer vaccines in development for various oncology indications sold to NeoTrail Therapeutics with an undisclosed purchase price NEW YORK and VIENNA, Austria, Feb. 03, 2026 (GLOBE NEWSWIRE [...]
Vivos Inc Updates Human Therapy Progress in India
03/02/2026
Kennewick, WA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to provide shareholders with a positive update on the ongoing human therapy demonstrations in India using RadioGel ® Precision [...]
MedRisk Acquires Horizon Casualty Services
03/02/2026
Strengthens MedRisk’s ability to deliver better outcomes and an elevated experience WEST CONSHOHOCKEN, Pa., Feb. 03, 2026 (GLOBE NEWSWIRE) -- MedRisk, a leading provider of managed care solutions for the workers’ [...]
Sangamo Therapeutics Announces Pricing of $25.0 Million Underwritten Offering
03/02/2026
RICHMOND, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the pricing of an underwritten offering consisting of 35,190,292 shares of its [...]
Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program
03/02/2026
Collaboration reinforces regulatory diligence, nonclinical strategy and clinical trial integrity for novel intranasal concussion therapy Traumatic brain injuries affect more Americans each year than stroke, Alzheimer’s [...]
Caring Brands Secures Two New U.S. Patents Strengthening Hair Enzyme Booster Technology
03/02/2026
Fort Pierce, FL, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Caring Brands Inc. (Nasdaq: CABR) today announced the issuance of two new United States patents covering proprietary methods and compositions designed to enhance [...]
Cynet Named a Strong Performer in 2026 Gartner Peer Insights™ “Voice of the Customer” for Endpoint Protection Platforms
03/02/2026
Customers cite Cynet’s “reliable endpoint protection” and “unified security platform” with 95% willingness to recommend BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Cynet , the unified, AI-powered cybersecurity platform, [...]
SRx Health Solutions Significantly Reduces Short Position of Cryptocurrency Portfolio Amidst Current Market Volatility
03/02/2026
NORTH PALM BEACH, Fla., Feb. 03, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") today announced it has significantly reduced its short position across its cryptocurrency [...]
Beghou Names Meredith Ressi as President and Chief Growth Officer
03/02/2026
Appointment reflects Beghou’s focus on scaling intelligently with integrated teams and technology to support clients throughout their commercialization journey EVANSTON, Ill., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Beghou , [...]
GT Biopharma Announces FDA Clearance of Investigational New Drug (IND) Application for GTB-5550 TriKE®, a B7-H3-Targeted Natural Killer (NK) Cell Engager for Solid Tumors Expressing B7-H3
03/02/2026
GTB-5550 Phase 1 dose escalation basket trial expected to initiate mid-2026 Phase 1 protocol allows multiple solid tumor types known to express B7-H3 Unaudited proforma cash balance as of January 31, 2026 of [...]
Nanox Receives FDA 510(k) Clearance for TAP2D New Image Enhancement Capability for Nanox.ARC and Nanox.ARC X Systems
03/02/2026
This clearance enables the next phase of development aimed ultimately at removing the adjunct use in the US The newly cleared capability provides radiologists with a 2D image generated directly from the tomosynthesis [...]
Femasys Expands European Commercial Footprint with Swiss Partner for FemBloc, FemaSeed, and Portfolio Products
03/02/2026
-- Multi-Product Distribution Agreement Marks Continued Commercial Momentum in Europe -- ATLANTA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator making fertility and non- [...]
aTyr Pharma Announces Scheduling of FDA Type C Meeting to Discuss Efzofitimod Program in Pulmonary Sarcoidosis
03/02/2026
Meeting with the FDA to review the results from the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis is scheduled for mid-April 2026. SAN DIEGO, Feb. 03, 2026 (GLOBE [...]
Mesa Labs Announces Third Quarter Results
03/02/2026
LAKEWOOD, Colo., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (“Mesa” or “the Company”), a global leader in the design and manufacture of life science tools and critical quality control [...]
Prelude Therapeutics Receives FDA Clearance of Investigational New Drug Application (IND) for PRT12396, a Mutant-selective JAK2V617F Inhibitor
03/02/2026
Phase 1 study of PRT12396 in patients with polycythemia vera and myelofibrosis anticipated to initiate by Q2 2026 WILMINGTON, Del., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a [...]
Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments
03/02/2026
This is the first time MEAI, Clearmind’s next-generation, non-hallucinogenic neuroplastogen, has been named in U.S. federal legislation Vancouver, Canada, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. ( [...]

Pages